104 related articles for article (PubMed ID: 11279974)
1. Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study.
Guerrero RO; Cárdenas MA; Ocampo AA; Pacheco MF
Headache; 1999 Sep; 39(8):576-80. PubMed ID: 11279974
[TBL] [Abstract][Full Text] [Related]
2. Nalpha-methyl histamine safety and efficacy in migraine prophylaxis: phase III study.
Millán-Guerrero RO; Isais-Millán R; Benjamín TH; Tene CE
Can J Neurol Sci; 2006 May; 33(2):195-9. PubMed ID: 16736729
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, double-blind study.
Millán-Guerrero RO; Isais-Millán R; Barreto-Vizcaíno S; Rivera-Castaño L; Garcia-Solorzano A; López-Blanca C; Membrila-Maldonado M; Muñoz-Solis R
Eur J Neurol; 2007 Oct; 14(10):1079-84. PubMed ID: 17880560
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study.
Millán-Guerrero RO; Isais-Millán R; Barreto-Vizcaíno S; Gutiérrez I; Rivera-Castaño L; Trujillo-Hernández B; Baltazar LM
Eur Neurol; 2008; 59(5):237-42. PubMed ID: 18264012
[TBL] [Abstract][Full Text] [Related]
5. N alpha methyl histamine versus propranolol in migraine prophylaxis.
Millán-Guerrero RO; Isais-Millán R; Guzmán-Chávez B; Castillo-Varela G
Can J Neurol Sci; 2014 Mar; 41(2):233-8. PubMed ID: 24534036
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous histamine versus botulinum toxin type A in migraine prophylaxis: a randomized, double-blind study.
Millán-Guerrero RO; Isais-Millán S; Barreto-Vizcaíno S; Rivera-Castaño L; Rios-Madariaga C
Eur J Neurol; 2009 Jan; 16(1):88-94. PubMed ID: 19087155
[TBL] [Abstract][Full Text] [Related]
7. [Subcutaneous histamine in migraine prophylaxis. Initial effects and long-term outcome].
Millán Guerrero R; Trujillo Hernández B; Tene CE
Neurologia; 2006 Mar; 21(2):55-9. PubMed ID: 16525910
[TBL] [Abstract][Full Text] [Related]
8. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
Diener HC; Bussone G; Van Oene JC; Lahaye M; Schwalen S; Goadsby PJ;
Cephalalgia; 2007 Jul; 27(7):814-23. PubMed ID: 17441971
[TBL] [Abstract][Full Text] [Related]
9. [New therapeutic alternatives in migraine prophylaxis using histamine H3 receptor agonists].
Millán-Guerrero RO; Isais-Millán R
Gac Med Mex; 2008; 144(4):291-5. PubMed ID: 18942262
[TBL] [Abstract][Full Text] [Related]
10. Nalpha-methylhistamine safety and efficacy in migraine prophylaxis: phase I and phase II studies.
Millán-Guerrero RO; Pineda-Lucatero AG; Hernández-Benjamín T; Tene CE; Pacheco MF
Headache; 2003 Apr; 43(4):389-94. PubMed ID: 12656710
[TBL] [Abstract][Full Text] [Related]
11. Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet.
Charlesworth BR; Dowson AJ; Purdy A; Becker WJ; Boes-Hansen S; Färkkilä M
CNS Drugs; 2003; 17(9):653-67. PubMed ID: 12828501
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
13. Diamine oxidase (DAO) supplement reduces headache in episodic migraine patients with DAO deficiency: A randomized double-blind trial.
Izquierdo-Casas J; Comas-Basté O; Latorre-Moratalla ML; Lorente-Gascón M; Duelo A; Soler-Singla L; Vidal-Carou MC
Clin Nutr; 2019 Feb; 38(1):152-158. PubMed ID: 29475774
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study.
Pfaffenrath V; Diener HC; Fischer M; Friede M; Henneicke-von Zepelin HH;
Cephalalgia; 2002 Sep; 22(7):523-32. PubMed ID: 12230594
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial.
Cady RK; Mathew N; Diener HC; Hu P; Haas M; Novak GP;
Headache; 2009 Feb; 49(2):216-26. PubMed ID: 19222595
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Modified Wuzhuyu Decoction Granule ( ) for Migraine Patients with Cold and Stasis Obstructing Meridian Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.
Liu HW; Zou YH; Cao KG; Yu LH; Zhang Y; Fu CH; Ma DY
Chin J Integr Med; 2018 Jun; 24(6):409-414. PubMed ID: 28741060
[TBL] [Abstract][Full Text] [Related]
18. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
19. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group.
Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.
Dodick DW; Goadsby PJ; Spierings EL; Scherer JC; Sweeney SP; Grayzel DS
Lancet Neurol; 2014 Sep; 13(9):885-92. PubMed ID: 25127173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
